Promising Covid-19 treatment pills are likely to take longer to reach patients in low- and middle-income countries than in rich ones because of manufacturing and pricing obstacles, despite efforts by drugmakers to make them more available, drug-access advocates and public-health experts say.

The pills promise to keep people who get infected from developing severe disease that requires hospitalization. They are already in use in the U.K. and nearing regulatory clearance in the U.S.